Chase Investment Counsel Corp Gilead Sciences, Inc. Transaction History
Chase Investment Counsel Corp
- $299 Million
- Q4 2024
A detailed history of Chase Investment Counsel Corp transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Chase Investment Counsel Corp holds 7,945 shares of GILD stock, worth $758,588. This represents 0.25% of its overall portfolio holdings.
Number of Shares
7,945Holding current value
$758,588% of portfolio
0.25%Shares
5 transactions
Others Institutions Holding GILD
# of Institutions
1,993Shares Held
993MCall Options Held
10.1MPut Options Held
8.85M-
Black Rock Inc. New York, NY121MShares$11.5 Billion0.19% of portfolio
-
Vanguard Group Inc Valley Forge, PA115MShares$11 Billion0.18% of portfolio
-
Capital World Investors Los Angeles, CA76.5MShares$7.31 Billion1.03% of portfolio
-
Capital Research Global Investors Los Angeles, CA61.8MShares$5.9 Billion1.12% of portfolio
-
State Street Corp Boston, MA60.2MShares$5.75 Billion0.21% of portfolio
About GILEAD SCIENCES, INC.
- Ticker GILD
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—General
- Shares Outstandng 1,253,369,984
- Market Cap $120B
- Description
- Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...